DavidLBushnellJr.MD

PubMed

• ASO Visual Abstract: Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.
  Luis C Borbon, Scott K Sherman, Patrick J Breheny, Chandrikha Chandrasekharan, Yusuf Menda
  Annals of Surgical Oncology. 2024-11-23
• Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.
  Luis C Borbon, Scott K Sherman, Patrick J Breheny, Chandrikha Chandrasekharan, Yusuf Menda
  Annals of Surgical Oncology. 2024-11-06
• 4 citations
  Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis.
  Liene Friebe, Martin T Freitag, Martin Braun, Guillaume Nicolas, Andreas Bauman
  Journal of Nuclear Medicine. 2024-02-01

Journal Articles

• Positron Emission Tomography, CT and MRI with Combidex for staging the mediastinum in NSCLC.  
  Kernstine K, Stanford W, Mullan B, Rossi N, Thompson B, Bushnell DL, McLaughlin K, Kern J, Annals Thorac Surg, 68:1022-1028
• Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.  
  Bushnell D, O’Dorisio T, Menda Y, Carlisle T, Zehr P, Connolly M, Karwal M, Miller S, Parker S, Bouterfa H, J Nucl Med, 44:1556-1560
• Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases.  
  Bushnell D, Menda Y, Madsen M, O’Dorisio T, Carlisle T, Zehr P, Ponto L, Karwal M, Parker S, Ponto J, Connolly M, Bouterfa H, Cancer Biother Radiopharm, 18 (4):581-588
• Enhancement of uptake of therapeutic radio-pharmaceuticals in bone lesions.  
  Bushnell D, Madsen M, Kahn D, Eur J Nucl Med, 30(2):331
• 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma.  
  Juweid ME, Menda Y, O’Dorisio MS, Bushnell D, Blake M, Madsen M, Johnson J, Graham M, Nucl Med Commun, 23(10):983-989
• Evaluation of various corrections to the standardized uptake value (SUV) for diagnosis of pulmonary malignancy.  
  Menda Y, Bushnell DL, Madsen M, Kernstine K, Nucl Med Comm, 22(10):1077-1081
• Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 diabetes mellitus (VA CSDM).  
  Pitale SU, Abraira C, Emanuele NV, McCarren M, Henderson WG, Pacold I, Bushnell DL, Diabetes Care, 23:1316-1320
• A threshold method to improve standardized uptake value reproducibility.  
  Lee JR, Madsen MT, Bushnell DL, Menda Y, Nucl Med Comm, 21:685-690
• Efficacy and safety of repeated Samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.  
  Menda Y, Bushnell DL, Williams RD, Miller S, Thomas M, Clin Nucl Med, 25:698-700
• The utility of Tc-99m Depreotide compared with FDG PET and surgical stapling in patients with suspected non-small-cell lung cancer.  
  Kahn D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, Berbaum K, Chest, 125(2):494-501
• Enhanced uptake of Tc-99m MDP in skeletal metastases from prostate cancer following initiation of hormone therapy: Potential for increasing delivery of therapeutic age...  
  Bushnell DL, Madsen M, Kahn D, Nathan M, Williams R, Nucl Med Comm, 20:875-881
• NeuroSPECT findings in patients with post-traumatic Anosmia: a quantitative analysis.  
  Varney NR, Bushnell DL, J Head Trauma and Rehab, 13:63-72
• Delayed Colonic transit in spinal cord injured patients measured by In-11 Amberlite scintigraphy.  
  Keshavarzian A, Barnes WE, Bruninga K, Nemchausky B, Bushnell DL, Am J Gastroenterol, 90:1295-1300
• Frequency of false positive septal defects on adenosine/Thallium-201 images in patients with left bundle branch block.  
  Patel R, Bushnell DL, Wagner R, Stumbris R, Nucl Med Commun, 16:137-139
• Neurobehavioral dysfunction following "mild" traumatic brain injury in childhood: a case report with positive PET findings.  
  Roberts MA, Manshadi FF, Bushnell DL, Hines ME, Brain Injury, 9:427-436
• Radioimmunoscintigraphy with 111-Indium labeled CYT-356 for the detection of occult prostate cancer recurrence.  
  Kahn D, Williams R, Seldin D, Libertino J, Hirschhorn M, Dreicer R, Weiner G, Bushnell DL, Gulfo J, J Urol, 152:1490-1495
• NeuroSPECT correlates of disabling minor head injury: preliminary findings.  
  Varney N, Bushnell DL, Nathan M, Kahn D, Roberts R, Rezai K, Kirchner PT, J Head Trauma and Rehab, 10:18-29
• Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.  
  Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M, J Nucl Med. 2010; 51:1524-31
• Treatment Of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules.  
  David Bushnell, Journal Of National Comphrehensice Cancer Network
• Nanets Consensus Guideline For The Diagnosis And Management Of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors Of The Jejunum, Ileum, Appendix, And Cecum.  
  J. Philip Boudreaux, Md, David S. Klimstra, Md,Þ Manal M. Hassan, Md, Phd, Eugene A. Woltering, Md, Robert T. Jensen, Md, Stanley J. Goldsmith, Md, Charles Nutting, Do..., Pancreas
• Nanets Treatment Guidelines: Well Differentiated Neuroendocrine Tumors Of The Stomach And Pancreas.  
  Matthew H. Kulke, Lowell B. Anthony, David Bushnell, Pancreas
• Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.  
  M. Sue O’Dorisio & Geetika Khanna & David Bushnell, Cancer Met Rev
• Retreatment of patients with metastatic bone disease with multiple doses of samarium.  
  Bushnell DL, Menda Y, Case studies in Oncology
• A quest for the relief of atherosclerosis: potential role of intrapulmonary heparin--A hypothesis  
  Kanabrocki EL, Bremner WF, Sothern RB, Gruber SA, Third JC, Bushnell DL, Olwin JH, Quarterly J Med 83:259-282
• Comparison of IMP and HMPAO for SPECT brain imaging.  
  Bushnell DL, Eastman G, Barnes WE, JNMT 19:71-74
• Join now to see all

Books/Book Chapters

• Medical Imaging of the Liver. 
  Chapter: Diagnostic imaging in hepatic trauma 
  Bushnell DL, Berg BEditors: Ruzika F, Polcyn RE, Wilson MA.Marcel Decker
• Textbook of Nuclear Medicine. 
  Chapter: SPECT Imaging of the brain 
  Bushnell DL, Perlman SBEditors: Wilson MA.Raven Press
• Textbook of Nuclear Medicine. 
  Chapter: Radionuclide imaging of the kidney 
  Perlman SB, Bushnell DL, Barnes WEEditors: Wilson MA.Raven Press
• Introduction to Radiology. 
  Chapter: Nuclear Imaging 
  Bushnell DLEditors: Erkonen W and Smith W.JB Lippincott
• Radiology 101: The Basics and Fundamentals of Imaging. 
  Chapter: Nuclear Imaging 
  Bushnell DLEditors: Erkonen W and Smith E.Lippincott Williams & WilkinsEdition 3,
• Join now to see all

Abstracts/Posters

• Tc-99m Depreotide tumor uptake in patients with non-Hodgkin’s lymphoma.
  Bushnell D, Menda Y, Madsen M, Link B, Truhlar S, Kahn D, Juweid M, Shannon M, Graham M, J Nucl Med 44:411P, Society of Nuclear Medicine Annual Meeting, New Orleans, LA
• Dosimetry results of oncolym in the treatment of refractory B-Cell non-Hodgkin’s lymphoma (NHL).
  Murray JL, Verkh L, Silver RT, Wessels BW, Varma VM, Kahn D, Bushnell DL, Annual Meeting of American Society of Clinical Oncology, Los Angeles
• Comparison of two of marrow absorbed dose estimates for patients treated with I-131 Lym-1 Antibody.
  Wessels B, Verkh L, Murray L, Silver R, Varma V, Kahn D, Bushnell DL, J Nucl Med 39:113, Society of Nuclear Medicine Annual Meeting, Toronto
• Influence of hydration state and cognitive performance on the CNS deposition of freely-diffusible substances.
  Ponto LLB, Popowski LA,Gisolfi CV, Johnson AK,Madsen MT, Watkins GL, Hichwa RD, Bushnell DL, AAPS Pharm Sci Supplement 1(4):S-123
• Standard uptake values using a fixed region threshold.
  Madsen M, Lee, Bushnell, DL, Menda Y, J Nucl Med 41:829p, Society of Nuclear Medicine Annual Meeting, St. Louis
• Retrospective analysis of standardized uptake values of lung masses with F-18 FDG PET.
  Menda Y, Bushnell DL, Madsen M, et al, J Nucl 41:1288p, Society of Nuclear Medicine Annual Meeting, St Louis
• Nonspecific mediastinal uptake of Tc-99m Depreotide (NeoTect).
  Menda Y, Kahn DK, Bushnell DL, Kernstine K, J Nucl Med 42:304p, Society of Nuclear Medicine Annual Meeting, Toronto
• Co-registration and Octreotide SPECT images of the abdomen with CT and MRI.
  Menda Y, Madsen MT, Bushnell DL, Hession WL, O’Dorisio T, Howe J, Graham MM, Society of Nuclear Medicine 48th Annual Meeting, Toronto
• Can FDG-PET reduce the need for mediastinoscopy (M) in potentially resectable non-small cell lung cancer (NSCLC)?
  Kernstine KH, McLaughlin KA, Menda Y, Rossi NP, Kahn DJ, Bushnell DL, Hashisho MM, Graham MM, Brown KK, Madsen M, Society of Thoracic Surgeons
• A new technique for staging potentially resectable lung cancer: NeoTect SPECT compared with F-18 FDG PET.
  Kernstine KH, Kahn D, Menda Y, McLaughlin K, Miller S, Bushnell D, et al, American Society of Clinical Oncology
• Prediction of post-test probability of malignancy of solitary pulmonary nodules.
  Graham MM, Menda Y, Bushnell DL, SNM 49th Annual Meeting 43:303P, Society of Nuclear Medicine Annual Meeting, Los Angeles
• Use of somatostatin receptor based scintigraphy (Octreoscan) in diagnosis and follow-up of neuroblastoma and medulloblastoma.
  O’Dorisio MS, Madsen M, Bushnell D, Menda Y, Juweid M, O’Dorisio TM, Pediatr Res 51:1436
• Clinical effectiveness of Y-90 DOTATOC therapy in patients with neuroendocrine tumors.
  O’Dorisio T, Menda Y, Zehr PS, Carlisle TL, Karwal MW, O’Dorisio MS, Bushnell DL, International Research Group in Immunoscintigraphy and Immunotherapy (IRIST), Rotterdam
• In-111-pentetreotide scintigraphy in the staging/restaging of neuroblastoma.
  Juweid M, Bartel T, Kemp A, Menda Y, Bushnell D, Twaddle J, Graham MM, American Society of Clinical Oncology (ASCO) Meeting, Chicago, IL
• In-111-pentetreotide scintigraphy in the staging/restaging of somatostatin-receptor positive pediatric tumors.
  Kemp A, Juweid M, Bartel T, Menda Y, Bushnell D, Twaddle J, O’Dorisio MS, Graham MM, J Nucl Med 44:348P, Society of Nuclear Medicine Annual Meeting, New Orleans, LA
• Detection of primary and recurrent carcinoid tumors with F-18-FDG PET: comparison with In-111-pentetreotide.
  Menda Y, O’Dorisio T, Floresca J, Bushnell DL, Juweid M, Graham MM, J Nucl Med 44:72P, Society of Nuclear Medicine Annual Meeting, New Orleans, LA
• Quick Interim results of a phase I-II trial of high dose samarium-153 EDTMP (Sm-153) in conjunction with total androgen blockade for patients with newly diagnosed pros...
  Higano CS, Bushnell, DL, Amerian Society of Clinical Oncology, Los Angeles
• Effects of intravenous amino acid administration with Y-90 DOTA-PHE1-TYR3-OCTREOTIDE (90Y-SMT487 (Octreother™)) treatment.
  Bushnell D, Menda Y, O’Dorisio T, Madsen M, Miller S, Carlisle T, Walkner W, Connolly M, Karwal M, Ponto J, Bouterfa H, Graham M, J Nucl Med 44:420P, Society of Nuclear Medicine Annual Meeting, New Orleans, LA
• Comparison of cardiac and hepatic uptake of Tc99m-tetrofosmin during adenosine stress myocardial perfusion studies to predict the presence of coronary artery disease.
  Squires SR, Bushnell DL, Menda Y, Graham MM, J Nucl Med 45:175P, Society of Nuclear Medicine Annual Meeting, Philadelphia, PA
• Predictive criteria for response of metastatic neuroendocrine tumors to therapy with Y-90 Octreotide.
  Nguyen V, Menda Y, Bushnell DL, O’Dorisio T, J Nucl Med 46(2):231P, Society of Nuclear Medicine Annual Meeting, Toronto, Canada
• Potential therapeutic advantage with combined I-131 MIBG and Y-90 DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC) for treating neuroendocrine tumors.
  Madsen MT, Bushnell DL, Menda Y, O’Dorisio T, J Nucl Med 46(2):448P, Society of Nuclear Medicine Annual Meeting, Toronto, Canada
• Optimized combined agent radionuclide therapy.
  Madsen M, Bushnell DL, J Nucl Med 47:220P, Society of Nuclear Medicine Annual Meeting, San Diego, CA
• Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC in the myeloablative setting for treatment of advanced neuroblastoma.
  Bushnell D, Juweid ME, Madsen M, Besse I, O’Dorisio T, Menda Y, O’Dorisio MS, Eur J Nucl Med Mol Imaging 33(2):S215, Annual Congress of the European Association of Nuclear Medicine, Athens, Greece
• FDG PET imaging of neuroendocrine tumors.
  Abraham T, Menda Y, O’Dorisio T, Bushnell D, Juweid M, Graham M, RSNA Annual Meeting, Chicago, IL
• Comparison of I-123 pre-therapy scintigraphy to post-therapy I-131 scintigraphy in postsurgical thyroid cancer patients.
  Thomas D, Bushnell D, Society of Nuclear Medicine Annual Meeting, New Orleans, LA
• Join now to see all

Lectures

• NANETS Neuroendocrine Tumor Symposium - "Emerging Targets & Therapeutic Advances in NET Management" 
  North American Neuroendocrine Tumor Society(NANETS), Charleston, South Carolina - 10/4/2013
• NANETS Neuroendocrine Tumor Symposium - "Emerging Targets & Therapeutic Advances in NET Management" 
  North American Neuroendocrine Tumor Society(NANETS), Charleston, South Carolina - 10/4/2013
• Samarium-153 EDTMP for Treatment of Skeletal Metastases. 
  Des Moines, Iowa
• Treatment of Bone Metastases using Radionuclides. 
  Iowa Subchapter of SNMT, Davenport, Iowa
• Radioimmunotherapy of Lymphoma. 
  Iowa Society of Radiologic Technologists, Cedar Rapids, Iowa
• Treatment of Painful Skeletal Metastases with Samarium-153 EDTMP. 
  Genesis Cancer Center, Davenport, Iowa
• Therapy with Samarium-153 EDTMP. 
  Mayo Clinic Oncology Seminar, Rochester, Minnesota
• PET imaging of Lymphoma, Melanoma, and Colorectal Cancer. 
  Central Chapter, Society of Nuclear Medicine, Chicago, Illinois
• Therapy with Radiolabeled Somatostatin Analogs. 
  Society for Surgery of the Alimentary Tract, Chicago, Illinois
• MIBG and PET in Neuroendocrine Tumors. 
  Society of Nuclear Medicine Annual Meeting, Toronto, Ontario, Canada
• Nuclear Medicine for Thyroid Disease. 
  39th Annual Iowa Head and Neck Cancer & Reconstructive Surgery Course, Iowa City, Iowa
• Nuclear Medicine and Neuroendocrine Tumors. 
  Missouri Valley Chapter of the Society of Nuclear Medicine, Coralville, Iowa
• Experience in the U.S. using Y-90 DOTATOC as therapy for NETs. 
  NANETS annual meeting, Norfolk
• Treatment of Neuroendocrine tumors with Y-90 DOTATOC. 
  North American Neuroendocrine Tumor Association, Bermuda
• Use of Imaging techniques for diagnosis and follow-up of Carcinoid tumors. 
  Caring for Carcinoid National Association, New Orleans, Louisiana
• Overview of Radionuclide imaging and therapy for neuroendocrine tumors. 
  Veterans Administration Regional Diagnostic Imaging Service-Line meeting Minneapolis
• Diagnostic Imaging techniques for neuroendocrine tumors. 
  NANETS annual meeting, Santa Fe
• Review and analysis of scientific presentations on neuroendocrine tumor imaging and therapy. 
  SNM Annual Meeting, San Antonio
• Functional SPECT Brain Imaging and Clinical Applications. 
  Madison, Wisconsin, 1988, Marshfield Hospital/Clinics, 1989
• Inelastic electron scattering studies of C Cl2F2, C Cl3F, C ClF3 with implications pertaining to the ozone depletion problem. 
  Argonne National Laboratories, Argonne, Illinois
• Diuretic Renal Scintigraphy. 
  Society of Wisconsin Nuclear Medicine Technologists, Madison, Wisconsin,
• Current Trends in the Evaluation of Regional Cerebral Blood Flow. 
  Annual Board Review Course for Neurology, Chicago, Illinois
• SPECT Evaluation of Ischemic Heart Disease. 
  Society of Wisconsin Nuclear Medicine Technologists, Madison, Wisconsin
• Review of Scintigraphic Application in Gastroenterology. 
  Cook County Graduate School of Medicine
• SPECT Imaging of the Heart and Brain. 
  Ottawa Community Hospital Medical Staff CME Program, Ottawa, Illinois
• Join now to see all

Other

• Commentary on the approach to diagnosing pulmonary embolism. 
  Bushnell DL, JCAH Abstracts of Clinical Care Guidelines, 3:14-15
• Glycemic control and complications in Type II diabetes: Design of a feasibility trial. 
  VA cooperative study group, Diabetes Care, 15:1560-1571
• Veterans affairs cooperative study on glycemic control and complications in type II diabetes: Results of the feasibility trial. 
  VACSDM study group, Diabetes Care, 18:1113-1123
• Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial. 
  VACSDM study group, Arch Int Med, 157:181-188
• Join now to see all